Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

“Yesterday, President Joe Biden declared that ‘it remains to be seen’ whether Artificial Intelligence (AI) is ‘dangerous.’ I would beg to differ,” said criminal defense attorney Jonathan Turley.